Avalyn Pharma

Senior Manager/Associate Director, SEC Reporting & Technical Accounting

Boston, MA · Director

Sponsorship not specified$166k-$186kDetected 27 days ago

ComplianceFinancial AnalysisAccountingFP&AResearchLeadershipCommunicationCollaborationGAAPSarbanes-OxleyFinancial ReportingInternal AuditNetSuite

About the role

About Avalyn Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases.
Avalyn's AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF).
Avalyn's AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA-IPF, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF).

Lead the preparation and timely filing of SEC reports, including Forms 10-K, 10-Q, 8-K, and S-8, and oversee XBRL tagging and related external reporting processes.
Own the preparation and review of financial statements, footnotes, and MD&A, ensuring compliance with U.S. GAAP and SEC regulations.
Partner with Legal, FP&A, Investor Relations, and senior leadership on earnings releases, proxy materials, and other public disclosures.
Research, evaluate, and document accounting conclusions for complex transactions and prepare technical accounting memoranda and policy documentation.
Support commercialization readiness by helping establish GAAP- and SOX-compliant revenue accounting and order-to-cash processes in partnership with Commercial, Market Access, Finance, and IT.
Design and implement internal controls over financial reporting as the company continues to build toward full SOX compliance.
Lead walkthroughs, risk assessments, control documentation, and remediation efforts in partnership with process owners and external consultants.
Support Section 16 reporting and related compliance requirements in coordination with legal counsel.
Coordinate PBC requests and support an efficient, well-organized audit process.

A minimum of a Bachelor's degree in Accounting or Finance required
6-8+ years of progressive accounting experience, including substantial SEC reporting and technical accounting experience in a public company environment.
A minimum of a Bachelor's degree in Accounting or Finance required; CPA required.
Experience in biotechnology, life sciences, or other R&D-intensive industries strongly preferred; experience with cell therapy revenue recognition is a plus.
CPA required.
Demonstrated experience building or enhancing SOX compliance programs.
Deep knowledge of U.S. GAAP and SEC regulations, including revenue recognition, equity compensation, and complex transaction accounting.
Experience with tools such as Active Disclosure, Equity Edge, NetSuite, or similar systems preferred.
Strong communication, sound judgment, and the ability to lead through influence in a fast-paced, mission-driven environment.
Proposed pay range
$166,000 - $186,000 USD

Big 4 or national public accounting firm experience strongly preferred.
Experience in biotechnology, life sciences, or other R&D-intensive industries strongly preferred
experience with cell therapy revenue recognition is a plus.

Manage quarterly reviews and annual audits and serve as the primary liaison with external auditors on technical accounting matters.

Strengthen scalable controls and operating processes across SEC reporting, technical accounting, and equity administration.
Lead equity accounting, including the calculation and recording of stock-based compensation in accordance with ASC 718.
Oversee external support for day-to-day stock administration activities and help ensure strong governance around equity-related processes.

This listing is sourced directly from Avalyn Pharma's careers page and normalized into a canonical job model.